Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 24, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically detailing activities related to the GlaxoSmithKline Employee Trust ("GSK Trust").
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes and Transactions
The following share transactions were advised to the Company on May 24, 2006, executed by the GSK Trust:
- May 19, 2006: Transfer of 11,482 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- May 22, 2006: Transfer of 12,620 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- May 22, 2006: Sale of 3,766 Ordinary Shares on behalf of participants in the GlaxSmithKline Share Value Plan at a price of GBP 14.95 per share.
- May 22, 2006: Transfer of 15,145 Ordinary Shares to participants in the GlaxSmithKline Share Value Plan.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding the company's operations were disclosed in this text.
Investor Verification Points
- Verify the total number of shares transferred or sold by the GSK Trust during the reporting period.
- Confirm the transaction price of GBP 14.95 per share for the GlaxSmithKline Share Value Plan sales.
- Review the specific interests of Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop in the GSK Trust.
- Note that this filing contains no financial performance data; refer to Form 20-F for comprehensive financial metrics.